NasdaqHealth CareHealth Care EquipmentS&P 500Nasdaq-100
$676.04
+5.33 (+0.79%)
Close of Nov 06, 2026 · end-of-day data
IDXX 8-K filings in 2025
Every material Form 8-K Idexx Laboratories filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 12, 2025, IDEXX Laboratories and its subsidiaries entered into Amendment No. 2 to its credit agreement with JPMorgan Chase Bank as administrative agent. The amendment extends the maturity of the $1.0 billion unsecured revolving credit facility to five years and provides for a term loan facility maturing in three years, giving the company longer-dated borrowing capacity. The filing does not state any amount drawn under the facilities.
Revolving credit facility of $1.0 billion extended to five years from the amendment closing date.
New term loan facility maturing three years from the closing date; the existing $250 million unsecured term loan is also referenced.
Credit agreement includes flexibility for up to $250 million in incremental revolving commitments and/or term loans.
Interest is priced at SOFR, CORRA, EURIBOR or other benchmark rates plus margins of 0.0% to 1.375% based on the consolidated leverage ratio.
IDEXX reported third quarter 2025 revenue of $1,105 million, up 13% as reported and 12% organic, and diluted EPS of $3.40, up 21%. The company raised its full-year 2025 revenue guidance to $4,270 million-$4,300 million and its EPS outlook to $12.81-$13.01, both signaling stronger expected results for shareholders.
Q3 2025 revenue of $1,105 million, up 13% as reported and 12% organic; CAG revenue up 14% and LPD up 17%.
Q3 diluted EPS of $3.40, up 21% as reported and 15% comparable; operating margin 32.1%, up 100 basis points.
2025 revenue guidance raised to $4,270 million-$4,300 million from $4,205 million-$4,280 million; EPS outlook raised to $12.81-$13.01 from $12.40-$12.76.
IDEXX Laboratories added Karen Peacock, former CEO of Intercom, as an independent Class I director effective October 6, 2025, and expanded its board from ten to eleven members. The filing describes her compensation and committee roles but reports no financial results or changes in company guidance.
Karen Peacock elected independent Class I director effective October 6, 2025; board increased from ten to eleven members
Peacock appointed to the Compensation and Talent Committee and Finance Committee
Her annual director equity grants will be made December 1, 2025, prorated from October 6, 2025 to the 2026 annual meeting
Expected to stand for stockholder election as a Class I director at the 2027 annual meeting
IDEXX Laboratories reported second-quarter 2025 revenue of $1,109 million, up 11% as reported and 9% organic, and diluted EPS of $3.63, up 49% as reported. The company raised its full-year 2025 revenue guidance to $4,205 million–$4,280 million and its EPS outlook to $12.40–$12.76, which shareholders will weigh against a prior-year litigation accrual that depressed the comparison base.
Q2 2025 revenue $1,109 million, up 11% as reported and 9% organic; comparable EPS $3.50, up 17%
Diluted EPS $3.63 included $0.07 from a discrete tax reserve release and $0.10 from share-based compensation tax benefits
2025 revenue guidance raised to $4,205 million–$4,280 million, up $90 million at midpoint; EPS outlook raised by $0.40 at midpoint to $12.40–$12.76
IDEXX Laboratories added Joseph L. (Jay) Hooley, former Chair and CEO of State Street Corporation, as an independent director effective July 10, 2025. The board expanded from nine to ten directors, and Mr. Hooley joined the Audit Committee and the Governance and Corporate Responsibility Committee. The filing reports no financial results or guidance changes; the appointment is a board governance change.
Joseph L. (Jay) Hooley elected as an independent Class III Director effective July 10, 2025
Board size increased from nine to ten directors; Class III seats increased from three to four
Appointed to the Audit Committee and Governance and Corporate Responsibility Committee
Director stock grants to Mr. Hooley scheduled for September 1, 2025, prorated to the 2026 annual meeting
IDEXX reported first-quarter 2025 revenue of $998 million, up 4% as reported and 5% organic, and diluted EPS of $2.96, up 5% as reported. The company raised its full-year 2025 revenue guidance to $4,095 million-$4,210 million and its EPS outlook to $11.93-$12.43, though part of the EPS gain came from a $0.08 litigation accrual adjustment.
Q1 2025 revenue was $998 million, up 4% as reported and 5% organic.
Diluted EPS was $2.96, up 5% as reported and 7% on a comparable basis, which excludes a $0.08 benefit from a discrete litigation expense accrual adjustment.
2025 revenue guidance was raised to $4,095 million-$4,210 million from $4,055 million-$4,170 million; EPS outlook rose to $11.93-$12.43 from $11.74-$12.24.
Organic revenue growth guidance of 6%-9% was maintained.
IDEXX Laboratories disclosed that director Dr. Asha Collins resigned from its Board of Directors effective immediately on February 13, 2025. The company said the resignation was not due to any disagreement over its operations, policies or practices, and it reduced the board size from ten to nine directors.
Dr. Asha Collins resigned from the Board effective immediately on February 13, 2025
The filing states the resignation was not due to any disagreement with the company on operations, policies or practices
IDEXX reported fourth quarter 2024 revenue of $954 million, up 6%, and EPS of $2.62, up 13% as reported. For the full year, revenue rose 6% to $3,898 million and EPS rose 6% to $10.67, after a $0.56 per share charge tied to an ongoing litigation matter. The company also issued initial 2025 guidance of $4,055 million to $4,170 million in revenue and $11.74 to $12.24 in EPS, and assumes about $1.5 billion of share repurchases.
Q4 2024 revenue of $954 million, up 6% as reported and organically; Q4 EPS of $2.62, up 13% as reported
Full year 2024 EPS of $10.67 included a $0.56 per share negative impact from a discrete litigation expense accrual
2025 outlook: revenue of $4,055 million to $4,170 million and EPS of $11.74 to $12.24, both initial estimates
Outlook assumes about $1.5 billion of share repurchases in 2025, subject to market conditions
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Idexx Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →